



# Source details

## International Journal of General Medicine

Open Access ⓘ

Scopus coverage years: from 2009 to 2022

Publisher: Dove Medical Press

ISSN: 1178-7074

Subject area: Medicine: General Medicine

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2021 ⓘ

1.2

SJR 2021 ⓘ

0.511

SNIP 2021 ⓘ

0.973

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

[Export content for category](#)

CiteScore rank ⓘ 2021 In category: General Medicine

☆ #435 International Journal of General Medicine 1.2 47th percentile  
826

☆ Rank Source title CiteScore 2021 Percentile

☆ #1 The Lancet 115.3 99th percentile

☆ #2 New England Journal of Medicine 110.5 99th percentile

☆ #3 National Vital Statistics Reports 53.1 99th percentile

☆ #4 Nature Reviews Disease Primers 46.1 99th percentile

☆ #5 The Lancet Global Health 41.8 99th percentile

☆ #6 JAMA - Journal of the American Medical Association 38.8 99th percentile

☆ #7 Annual Review of Public Health 35.5 99th percentile

☆ #8 Annual Review of Pathology: Mechanisms of Disease 34.0 99th percentile


☆ #9 Science Robotics 32.6 98th percentile

☆ #10 Annual review of food science and technology 25.7 98th percentile

☆ #11 Military Medical Research 22.5 98th percentile

☆ #12 Annual Review of Physical Chemistry 21.7 98th percentile

### CiteScore trend



## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





## Submit Your VMI Journal Paper

Hindawi's Academic Journals Cover A Wide Range of  
With Us.

Hindawi

## International Journal of General Medicine

### COUNTRY

New Zealand



Universities and research  
institutions in New  
Zealand

### SUBJECT AREA AND CATEGORY

Medicine  
Medicine  
(miscellaneous)

### PUBLISHER

Dove Medical Press Ltd.

### H-INDEX

40

### PUBLICATION TYPE

Journals

### ISSN

11787074

### COVERAGE

2009-2021

### INFORMATION

[Homepage](#)

[How to publish in this  
journal](#)

### SCOPE






The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal. As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.


Join the conversation about this journal

Quartiles


FIND SIMILAR JOURNALS ?

Rank	Journal Name	Country	Similarity
1	Journal of Investigative Medicine	USA	57%
2	Acta Clinica Belgica	GBR	57%
3	Postgraduate Medical Journal	GBR	56%
4	American Journal of Medical Science	USA	55%






% International Collaboration





Citable documents

Non-citable documents



Cited documents

Uncited documents



**International Journal of General Medicine**

Q2 Medicine (miscellaneous) best quartile

SJR 2021 0.51

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool**.



Metrics based on Scopus® data as of April 2022

A **Ali Ali Saadoon** 2 years ago

dear all good evening .....

if possible, I need the whats app phone as a trial for communication with you

reply

Back to [Journals](#) » [International Journal of General Medicine](#) » [Volume 14](#) » default

7 | 9 | 5 | 9 | 7

## Papers Published

Submit New Manuscript

Login to view existing manuscript status

Signup for Journal alerts

## About Dove Press

Open access peer-reviewed scientific and medical journals.

[Learn more](#)

## Open Access



Dove Medical Press is a member of the OAI.

[Learn more](#)

## Reprints

Bulk reprints for the pharmaceutical industry.

[Learn more](#)

## Favored Authors

We offer real benefits to our authors, including fast-track processing of papers.

[Learn more](#)

## Promotional Article Monitoring

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.

[Learn more](#)

SJR OA (SJR SCIMAGO JOURNAL & COUNTRY RANK) CITESCORE () IMPACT FACTOR (JOURNAL IMPACT FACTOR: 2.145)

## International Journal of General Medicine



[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)

<a href="#">View all</a> (2811)	<a href="#">Volume 16, 2023</a> (15)	<a href="#">Volume 15, 2022</a> (764)
<b>Volume 14, 2021</b> (991)	<a href="#">Volume 13, 2020</a> (199)	<a href="#">Volume 12, 2019</a> (62)
<a href="#">Volume 11, 2018</a> (59)	<a href="#">Volume 10, 2017</a> (56)	<a href="#">Volume 9, 2016</a> (55)
<a href="#">Volume 8, 2015</a> (54)	<a href="#">Volume 7, 2014</a> (67)	<a href="#">Volume 6, 2013</a> (119)
<a href="#">Volume 5, 2012</a> (139)	<a href="#">Volume 4, 2011</a> (125)	<a href="#">Volume 3, 2010</a> (54)
<a href="#">Volume 2, 2009</a> (35)	<a href="#">Volume 1, 2008</a> (16)	



### Archive: Volume 14, 2021

ORIGINAL RESEARCH

#### Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer

Lu Y, Tang W, Wang X, Kang X, You J, Chen L

[International Journal of General Medicine 2021](#), 14:10541-10555

Published Date: **31 December 2021**

ORIGINAL RESEARCH

#### Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study

Rachman A, Shatri H, Salamat R

[International Journal of General Medicine 2021](#), 14:10527-10539

Published Date: **31 December 2021**

ORIGINAL RESEARCH

#### The Lactate/Albumin Ratio Predicts Mortality in Critically Ill Patients with Acute Kidney Injury: An Observational Multicenter Study on the eICU Database

Zhu X, Xue J, Liu Z, Dai W, Xu H, Zhou Q, Zhao S, Zhou Q, Chen W

[International Journal of General Medicine 2021](#), 14:10511-10525

Published Date: **30 December 2021**

ORIGINAL RESEARCH

#### The Relationship Between Blood Lipid and Attention-Deficit/Hyperactivity Disorder (ADHD) in an Obese Population of Chinese Children: An Obesity-Stratified Cross-Sectional Study

Xu Y, Bao L, Liu C

[International Journal of General Medicine 2021](#), 14:10503-10509

Published Date: **30 December 2021**

Kamińska J, Stopiński M, Mucha K, Pac M, Gołębiowski M, Niewczas MA, Pączek L, Foroniewicz B

[International Journal of General Medicine 2021](#), 14:2413-2420

Published Date: **9 June 2021**

ORIGINAL RESEARCH



### **Modified Chest X-Ray Scoring System in Evaluating Severity of COVID-19 Patient in Dr. Soetomo General Hospital Surabaya, Indonesia**

Setiawati R, Widyaningroem A, Handarini T, Hayati F, Basja AT, Putri ARDS, Jaya MG, Andriani J, Tanadi MR, Kamal IH

[International Journal of General Medicine 2021](#), 14:2407-2412

Published Date: **9 June 2021**

REVIEW

### **Etiological Factors of the Midline Diastema in Children: A Systematic Review**

Nuvvula S, Ega S, Mallineni SK, Almulhim B, Alassaf A, Alghamdi SA, Chen Y, Aldhuwayhi S

[International Journal of General Medicine 2021](#), 14:2397-2405

Published Date: **8 June 2021**

ORIGINAL RESEARCH



### **COVID-19 Vaccine Acceptance and Its Associated Factors Among Pregnant Women Attending Antenatal Care Clinic in Southwest Ethiopia: Institutional-Based Cross-Sectional Study**

Mose A, Yeshaneh A

[International Journal of General Medicine 2021](#), 14:2385-2395

Published Date: **8 June 2021**

ORIGINAL RESEARCH

### **The Effect of Sodium Hyaluronate on the Corneal Biomechanics of Patients with Cataract and Dry Eye Before Operation**

Chen N, Zhang JS, Zhang TX, Shao YS, Zhang F

[International Journal of General Medicine 2021](#), 14:2377-2384

Published Date: **8 June 2021**

ORIGINAL RESEARCH

### **miR-328-3p, a Predictor of Stroke, Aggravates the Cerebral Ischemia-Reperfusion Injury**

Wang S, Jun J, Cong L, Du L, Wang C

[International Journal of General Medicine 2021](#), 14:2367-2376

Published Date: **8 June 2021**

CLINICAL TRIAL REPORT



### **Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study**

Di Pierro F, Derosa G, Maffioli P, Bertuccioli A, Togni S, Riva A, Allegrini P, Khan A, Khan S, Khan BA, Altaf N, Zahid M, Ujjan ID, Nigar R, Khushk MI, Phulpoto M, Lail A, Devrajani BR, Ahmed S

[International Journal of General Medicine 2021](#), 14:2359-2366

Published Date: **8 June 2021**

ORIGINAL RESEARCH

### **Clinical Analysis and Management of Long-Stay Patients**

Huang C

[International Journal of General Medicine 2021](#), 14:2351-2357

Published Date: **4 June 2021**

ORIGINAL RESEARCH

### **Predictive Value of Limb Artery Indices and Endothelial Functional Tests for the Degree of Coronary Artery Stenosis in a Diabetic Population**

Wang Z, Chen Y, Lv S, Sun Z, Lu X, Huang L, Li L

[International Journal of General Medicine 2021](#), 14:2343-2349

Published Date: **3 June 2021**

ORIGINAL RESEARCH

[Submit New Manuscript](#)

[Login to view existing manuscript status](#)

[Signup for Journal alerts](#)

### About Dove Press

Open access peer-reviewed scientific and medical journals.

[Learn more](#)

### Open Access

Dove Medical Press is a member of the OAI.

[Learn more](#)

### Reprints

Bulk reprints for the pharmaceutical industry.

[Learn more](#)

### Favored Authors

We offer real benefits to our authors, including fast-track processing of papers.

[Learn more](#)

### Promotional Article Monitoring

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.

[Learn more](#)

### Social Media

Back to [Journals](#)

SJR OA (SJR SCIMAGO JOURNAL & COUNTRY RANK) CITESCORE () IMPACT FACTOR (JOURNAL IMPACT FACTOR: 2.145)

## International Journal of General Medicine



[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)

[Article Publishing Charges](#) | [Aims and Scope](#) | [Call For Papers](#) | [Podcasts](#)

### Dr Fraser

Consultant Ophthalmologist, Sunderland Eye Infirmary, United Kingdom

EDITOR IN CHIEF

#### Editor-in-Chief: Professor Scott Fraser

Professor Scott Fraser is a consultant ophthalmologist at Sunderland Eye Infirmary in the North East of the UK. He is also honorary lecturer at the University of Newcastle Upon Tyne and visiting professor at the University of Sunderland. He is a member of the Royal College of Surgeons of Edinburgh and the Royal College of Ophthalmologists.



Dr Fraser

He trained as an ophthalmologist initially in Newcastle and then completed his training at Moorfields Eye Hospital. At Moorfields he was also a research fellow initially looking into risk factors for late presentation of glaucoma and later as the Friend of Moorfields funded researcher looking at the genetics of glaucoma. He was awarded his MD in 2000.

His main clinical interest is in glaucoma in which he completed sub-speciality training at Moorfields. His research interests also include glaucoma but more widely he is interested in factors that alter compliance with eye medications. He also has an interest in evidence based medicine and is an editor for the Cochrane Eyes and Vision group. He has published over 50 peer reviewed articles and over 100 presentations at scientific meetings. He has written chapters for 7 textbooks and has co-written a manual for eye care.

### Dr Castellani

Urology, Urology Division, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Polytechnic University, Italy

ASSOCIATE EDITOR IN CHIEF

#### Associate Editor: Dr. Daniele Castellani

##### Section: Urology

Dr Daniele Castellani is an attending physician in the Urology Department at the University Hospital Ospedali Riuniti di Ancona, Polytechnic University of Le Marche, Ancona, Italy. He is a member of the European Association of Urology. Dr Castellani received his medical degree from the La Sapienza University in Rome, Italy. He was a medical resident in urology, at the University of L'Aquila, Italy.



Dr Castellani

Dr Castellani's research interests include benign prostatic hyperplasia, uro-oncology, lasers in urology, and urolithiasis.

Dr Castellani is member of the editorial board of several scientific journals. He has published 90 papers in index journals.





Need help?

## **Prof. Dr. Jakovljevic**

Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Japan, Japan

ASSOCIATE EDITOR IN CHIEF

### **Associate Editor: Prof. Mihajlo (Michael) Jakovljevic**

#### **Section: Public Health**

Professor Mihajlo (Michael) Jakovljevic M.D. Ph.D. MAE published approx. 300 papers in indexed, peer reviewed journals (Hirsch Factor 62; Citations Count<sup>~</sup> 66,800+; Cumulative Impact Factor app. 2000+; i-10 index 165).

Being a professional health economist and clinical pharmacology physician, his expertise focuses on Emerging Markets and sustainability of health financing

across LMICs countries worldwide. In Editor-in-Chief capacity he leads prestigious Cost Effectiveness and Resource Allocation, BMC journal since 2019 (IF=2.532) and was Founding Specialty Editor-in-Chief of Frontiers in Health Economics, based in Lausanne, Switzerland in 2016-2021 mandate (IF=3.709).

He is Professor and Founding Head of The Global Health, Economics and Policy Department at The University of Kragujevac situated in the historical capital of Serbia. He holds a JSPS funded Visiting Professorship at the Institute of Comparative Economic Studies, Hosei University Tokyo Japan. He is also an Expert affiliate of the CHTF IHME University of Washington since 2016 and used to hold a FORTE-funded Visiting Research Fellow position at Lund University, Sweden in the Division of Health Economics in 2018.

For his achievements and professional standing, in 2015 he became the first-ever nominated candidate from Eastern Europe for IHEA (International Health Economics Association) Board of Directors Elections. Over the past twenty years he has delivered plenary lectures and solicited speeches in well over thirty countries across Eurasia. During the past decade he continues to serve as Scientific Committee Member in top tier health economics and demography events such as IHEA, EuHEA, World Sustainability Forum. Since 2018 he continues as a WHO EACHR Committee member in an advisory capacity to the Cabinet of WHO Regional Director for Europe, based in Copenhagen, Denmark. In November 2021 he became first-ever Elected Ordinary Academician coming from Serbia, at the UNESCO World Academy of Sciences TWAS with its headquarters in Trieste, Italy. In June 2022 he was elected to Full Membership within Academia Europea, London, UK.



Prof. Dr. Jakovljevic

## **Dr Kung**

Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan

ASSOCIATE EDITOR IN CHIEF

### **Associate Editor: Prof. Dr. Woon-Man Kung**

#### **Section: General Medicine**

Woon-Man Kung received his M.D. degree from the School of Medicine, Taipei Medical University (TMU), Taipei, Taiwan in 1999. In 2012, he received his M.Sc. degree in Biomedical Engineering from the College of Medicine and College of Engineering, National Taiwan University (NTU), Taipei, Taiwan. Dr. Kung now serves as a Consultant Neurosurgeon in the Division of Neurosurgery,

Department of Surgery, Taipei Tzu Chi Hospital (TCH), Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, as well as an Adjunct Associate Professor in the

Department of Exercise and Health Promotion, College of Kinesiology and Health, Chinese Culture University (CCU), Taipei, Taiwan. He further participates as an International Membership of the professional association at the Congress of Neurological Surgeons (CNS), USA. He currently works in the Editorial/Advisory Board of several indexed journals and involves acting as an ad-hoc reviewer for a number of prestigious scientific journals.



Dr Kung

## **Professor Leffert**

Department of Pharmacology, School of Medicine, University of California at San Diego (UCSD), United States

ASSOCIATE EDITOR IN CHIEF

### **Associate Editor: Prof. Hyam Leffert**

#### **Section: Hepatology**

Professor Leffert attended the University of Rochester, Rochester, NY (B.A., Intellectual History, 1965), where he studied Necturus blood cells with Professor Ernst Caspari; Brandeis University, Waltham, Mass (M.A., Biology, 1967), where he reconstituted a primary immune response in vitro with Professor Gordon Sato; and the Albert Einstein College of Medicine, Bronx, NY (M.D., 1971), where he discovered a lecithinase-producing *Bacillus cereus* in a newborn suffering from Meningitis and bacteremia after ventriculoatrial shunt-revision (he identified the organism by its GC-base composition with Professor Julius Marmur).

His internship at UCSD (La Jolla, CA, 1972) was split between Pediatrics, and Biology, where he developed selection methods to culture proliferation- and differentiation-competent primary hepatocytes for use as model systems of liver development and regeneration.

Dr. Leffert continued basic research at the Salk Institute, where, as an NCI/NIH/Damon Runyon Cancer Research Fellow and an Assistant Professor of Cell Biology, he directed liver growth control studies alongside many students, postdocs, and sabbatical visitors through 1980. Several growth factors were discovered (insulin, glucagon and epidermal growth factor; thereafter, insulin-like growth-factors IGF-I and IGF-II and TGF- $\alpha$ ). Later studies provided molecular understanding of relationships between growth factors, regeneration and the expression and biochemistry of cyclins D1, B, A and E. Drs. Koch and Leffert, and Stewart Sell, UCSD Professor of Pathology, also observed expression of  $\alpha$ -fetoprotein, a clinical marker of human hepatocellular carcinoma, in neonatal hepatocytes undergoing liver development in vitro and in vivo, and in normal long-term primary hepatocyte cultures simulating liver regeneration. Further work revealed that primary hepatocytes enzymatically converted chemical procarcinogens like N-Acetyl-2-Aminofluorene (AAF) into carcinogenic metabolites -- research that enabled precision drug metabolism studies by the pharmaceutical industry. In 1987, with Professor Ted Friedmann (UCSD Pediatrics), Dr. Leffert introduced genes into hepatocytes using retroviral vectors (initiating hepatic gene therapy research). Dr. Leffert was awarded a John Simon Guggenheim Memorial Fellowship, and a Morton Grossman Research Scholar Award by the American Gastroenterological Association, to study Molecular Cancer Genetics with Sir Henry Harris at the Sir William Dunn School of Pathology at Oxford University.

Currently, Drs. Leffert, Koch and Sell, are focused upon determination of pharmacokinetic growth cycle-dependent metabolic and covalent binding parameters of AAF, and the implication these new findings have with respect to translesion hepatocyte DNA synthesis and the chemical induction of hepatocellular carcinoma.

### **Prof. Dr. Mora-Montes**

Departamento de Biología, Universidad de Guanajuato, Mexico

[ASSOCIATE EDITOR IN CHIEF](#)

#### **Associate Editor: Prof. Héctor M. Mora Montes**

During his post as a clinical analyst, Prof. Mora-Montes developed a system for the differentiation of *Candida* species, based on in-house zymograms and colony morphology in cornmeal agar. As a postgraduate student, he generated a new and innovative method for in situ determination of glycosyl hydrolase activities and received the "Summa Cum Laude" distinction from Universidad de Guanajuato. Among the most important achievements during his time as a postdoctoral fellow at the University of Aberdeen (Scotland), he set up most of the immunological techniques within the Aberdeen Fungal Group and developed and standardized protocols for the isolation and purification of chitin, phospholipomannan, N-linked and O-linked mannans from fungal cells. Those protocols have not only benefited the Aberdeen Fungal Group, but other international groups dedicated to the study of the fungal cell wall, and are considered among the most popular and standardized methods for isolation and analysis of fungal cell wall components. In 2010, he established the Laboratory of Fungal Glycobiology at Universidad de Guanajuato (Mexico), with the main goal to understand the mechanisms behind the fungal cell wall synthesis and the interaction of medically relevant fungal pathogens with the host. This laboratory is characterized by its facilities to perform chemical, immunological, genetic, molecular and cellular analyses of human fungal pathogens. Therefore, it is among a handful of research facilities within Mexico and Latin America offering a multidisciplinary and integral approach to understand these pathogens. Currently, the group is developing molecular tools for genetic manipulation of medically relevant fungi, in particular *Sporothrix* and *Candida* species. Our group has a solid international reputation in the genetic study of these organisms, in the immune sensing of fungal cells, and the development of alternative models to analyze fungal virulence. Since 2016, he was awarded the level III distinction by SNI, the highest distinction awarded by the Mexican Government for Mexican Researchers under 65 years old. He currently holds editorial appointments in several peer-reviewed international journals and is the Deputy President of the Latin-American Society of Glycobiology.



Professor Leffert



Prof. Dr. Mora-Montes

## Professor Nair

College of Medicine, Tawam Hospital, UAE University, Al Ain, United Arab Emirates

ASSOCIATE EDITOR IN CHIEF

### Associate Editor: Prof. Satish Chandrasekhar Nair

#### Section: Public Health

Professor Satish Chandra has the unique distinction of serving at senior positions in the pharmaceutical industry and, at academic medical centers in the USA, India and the United Arab Emirates, for over 25 years. He obtained his PhD (faculty of medicine) following graduation from the TN Medical College. In addition, he is American Board certified in medical quality, and informatics. He further obtained MBA in healthcare management from the University of Nebraska. He has proven expertise in clinical trials, designing clinical trails, research ethics, medical ethics, joint commission hospital accreditation, patient safety, medical quality and public health. He has over 100 international peer reviewed PubMed indexed publications. His publications include Lancet, Breast Cancer, International Journal Public health and other reputed publications. He serves on the editorial board of several international journals, and was awarded several global awards such as the Technology Pioneer, Marcus Evans best speaker, and innovative professional awards from the USA, Switzerland, Japan and the UAE. He has authored several COVID-19 publications recently. He is currently the associate professor, college of medicine, UAE University, and the Director for clinical research at Tawam Hospital, Al Ain, UAE. He is involved in medical residency research training.



Professor Nair

## Prof. Dr. Reis

Urology, University of Campinas, Brazil

ASSOCIATE EDITOR IN CHIEF

### Associate Editor: Prof. Dr. Leonardo Oliveira Reis

#### Section: Urology

Leonardo Oliveira Reis is Professor of Urology and Uro-Oncology at the State University of Campinas, Unicamp and the Pontifical Catholic University of Campinas, PUC-Campinas, Fulbright Visiting Professor at Harvard University, Urology Fellow at Columbia University, New York, NY, USA (American Urological Association, 2011). Postdoctoral Fellow at The Johns Hopkins University, School of Medicine, Baltimore, MD, USA (CAPES, 2014-2015). Research Productivity 1 of the Brazilian National Council for Scientific and Technological Development, CNPq, aimed at researchers who stand out among their peers according to normative criteria. Has experience in Urology, with emphasis on Urological Oncology. He is the author/co-author of >200 scientific articles indexed by PUBMED, >40 Chapters of National and International Books, Top Reviewer @Publons, CAPES Theses Award 2012 Medicina III (Surgery). National and International Ad hoc advisor. Executive Member of the World Urologic Oncology Federation (WUOF). AUA International Member and Scholar. Handling Editor for the World Journal of Urology (Springer), ex-official journal of the Société Internationale d'Urologie (SIU), and Associate and Section Editor, International Brazilian Journal of Urology (IBJU), the official journal of the Brazilian Society of Urology (SBU), and the American Confederation of Urology (CAU). Scientific Director (2018-19) of the Brazilian Society of Urology (SBU), São Paulo Section. President of the Human Ethics Committee for Research (2016-2019) of the Pontifical Catholic University of Campinas, PUC-Campinas. Latin America Top Scientist (AD Scientific Index 2021, 2022).



Prof. Dr. Reis

## Professor Rodríguez-Morales

Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Colombia

ASSOCIATE EDITOR IN CHIEF

### Associate Editor: Prof. Alfonso J. Rodríguez-Morales

#### Section: Infectious Diseases

Dr. Rodríguez-Morales is an expert in tropical and emerging diseases, particularly in zoonotic and vector-borne diseases (especially arboviral diseases), now including COVID-19 and Monkeypox. He is President of the Publications and Research Committee of the Pan-American Infectious Diseases Association (API), as well as President of the Colombian Association of Infectious Diseases (ACIN). He is a member of the Committee on Tropical Medicine, Zoonoses, and Travel Medicine of ACIN. He is Vice President of the Latin



Professor Rodríguez-Morales

# Modified Chest X-Ray Scoring System in Evaluating Severity of COVID-19 Patient in Dr. Soetomo General Hospital Surabaya, Indonesia

Rosy Setiawati <sup>1</sup>  
Anita Widyoningroem <sup>1</sup>  
Triwulan Handarini <sup>1</sup>  
Fierly Hayati <sup>1</sup>  
Agnes Triana Basja <sup>1</sup>  
Atrikha Rahma Dyana Surya Putri <sup>1</sup>  
Merlin Guntur Jaya <sup>2</sup>  
Jessica Andriani <sup>2</sup>  
Melina Rosita Tanadi <sup>2</sup>  
Imran Harsam Kamal <sup>2</sup>

<sup>1</sup>Department of Radiology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital Surabaya, Surabaya, Indonesia; <sup>2</sup>Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia

**Introduction:** The management of COVID-19 patients requires efficiency and accuracy in methods of detection, identification, monitoring, and treatment feasible in every hospital. Aside from clinical presentations and laboratory markers, chest x-ray imaging could also detect pneumonia caused by COVID-19. It is also a fast, simple, cheap, and safe modality used for the management of COVID-19 patients. Established scoring systems of COVID-19 chest x-ray imaging include Radiographic Assessment of Lung Edema (RALE) and Brixia classification. A modified scoring system has been adopted from BRIXIA and RALE scoring systems and has been made to adjust the scoring system needs at Dr. Soetomo General Hospital, Indonesia. This study aims to determine the value of scoring systems through chest x-ray imaging in evaluating the severity of COVID-19.

**Methods:** Data were collected from May to June of 2020 who underwent chest x-ray evaluation. Each image is then scored using three types of classifications: modified score, RALE score, and Brixia score. The scores are then analyzed and compared with the clinical conditions and laboratory markers to determine their value in evaluating the severity of COVID-19 infection in patients.

**Results:** A total of 115 patients were males (51.1%) and 110 were females (48.9%). All three scoring systems are significantly correlated with the clinical severity of the disease, with the strengths of correlation in order from the strongest to weakest as Brixia score ( $p < 0.01$ , correlation coefficient 0.232), RALE score ( $p < 0.01$ , correlation coefficient 0.209), and Dr. Soetomo General Hospital score ( $p < 0.01$ , correlation coefficient 0.194). All three scoring systems correlate significantly with each other. Dr. Soetomo General Hospital score correlates more towards Brixia score ( $p < 0.01$ , correlation coefficient 0.865) than RALE score ( $p < 0.01$ , correlation coefficient 0.855). Brixia to RALE score correlates with a coefficient of 0.857 ( $p < 0.01$ ).

**Conclusion:** The modified scoring system can help determine the severity of the disease progression in COVID-19 patients especially in areas with shortages of facilities and specialists.

**Keywords:** Brixia score, chest radiographs, COVID-19, modified score, RALE score

## Introduction

COVID-19 appeared in Wuhan, China on the late December 19 with fever, cough, and myalgia as the most common symptoms.<sup>1</sup> The disease manifests in varying degrees from mild to severe and may progress to acute respiratory distress syndrome (ARDS).<sup>2</sup> In current cases, the fatality rate of COVID-19 varies between countries, although the exact number of mortality rate remains unknown, due to the

Correspondence: Rosy Setiawati  
60286  
Tel +62 878 5330 0019  
Email rosy-s@fk.unair.ac.id



number of asymptomatic cases.<sup>3</sup> Within only a few months, the pathogen had spread all over the world and contributed to a 3–5% of mortality.<sup>4</sup> By the end of March 2020, the Case Fatality Rate (CFR) of COVID-19 in Indonesia was 8.9%. This is higher than the mean CFR all over the world.<sup>5</sup> Radiological examination is reported to play an important role in the diagnosis of COVID-19. A systematic review of case series with a total of 919 patients in China and Korea suggested that chest X-ray (CXR) may not be reliable for diagnosing COVID-19 in its early stage. Only in its intermediate and severe stages is when COVID-19's feature of the lungs is seen on CXR. The British Society of Thoracic Imaging (BSTI) suggested chest radiography to all seriously ill patients (oxygen saturation <94%, National early warning score (NEWS) >3) and if "clinically required".<sup>6</sup> On the other hand, chest computed tomography (CT) could provide a more accurate identification of severe lung diseases in COVID-19 with a sensitivity of 83.3% and a specificity of 94%.<sup>7</sup> Although chest-CT is more sensitive and specific than CXR, interpreting CXRs had always been a routine practice for clinicians to rule out other causes of respiratory disease.<sup>8</sup> The lack of CT-scans and radiologists, especially in developing countries such as Indonesia, makes CXR a great substitute to diagnose and determine the severity and progression of lung abnormalities in COVID-19 patients.<sup>9</sup>

The currently established CXR scoring systems are Brixia and Radiographic Assessment of Lung Edema (RALE) scoring systems. Brixia scoring system has been widely used as a tool to monitor the severity and progression of COVID-19 pneumonia in Tongji Hospital, Wuhan and Azienda Socio Sanitaria Territoriale, Spedali Civili of Brescia, Italy.<sup>10</sup> RALE scoring system, presented by Wong et al, has been used in Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital, Hong Kong; The University of Hong Kong; Shenzhen Hospital, Shenzhen; and University Hospital Careggi.<sup>11–13</sup> One of the important differences between the two scorings is that RALE can be done by a general practitioner due to its simplicity, while Brixia is designed to be used by a trained radiologist. The RALE scoring system only divides the lung into two regions, making it not specific to smaller lesions.<sup>14</sup>

Seeing the current conditions regarding the lack of distribution of trained radiographers and radiologists in Indonesia, we proposed a CXR scoring system for evaluating the severity of COVID-19 patients in Dr. Soetomo General Hospital, Surabaya, Indonesia. A modified scoring

system has been adopted from Brixia and RALE scoring systems, and has been made to adjust to the needs and resources of Dr. Soetomo General Hospital Surabaya, Indonesia. This scoring system is aimed to be applicable to mild pneumonia cases and provide a faster and more accurate analysis. This study aims to determine the value of scoring systems through CXR imaging in evaluating the severity of COVID-19.

## Materials and Methods

This is a retrospective study of patients with RT-PCR-confirmed COVID-19 in Dr. Soetomo General Hospital. This study was conducted in accordance with the Declaration of Helsinki. This study was approved by the Medical Research Ethics Committee of Dr. Soetomo General Hospital, Surabaya. All participants included had given their written informed consent to participate in this study during admission. In cases of decreased consciousness and severe illness, written informed consent was represented by next of kin.

We included 225 patients who came to the emergency ward and outpatient clinic from May – June 2020. Patients with symptoms and who had RT-PCR-confirmed COVID-19 and positive CXR abnormalities were included. In this study, we analyzed the initial CXR of when the patient was first admitted. The CXRs were analyzed by 2 radiologists with an experience of more than 10 years.

Chest radiographs were acquired following the usual protocols and performed with posteroanterior or antero-posterior projection. The radiographs were then interpreted as normal or abnormal. The abnormalities are described by the distribution (upper zone predominant, middle zone predominant, or lower zone predominant), side (right or left lung), and peripheral or perihilar dominance. Other features, such as pleural effusions and nodules, will also be mentioned.

The severity based on the imaging was calculated using Brixia, RALE, and the Dr. Soetomo General Hospital scoring system (Modified Chest X-ray Scoring System).

Brixia scoring system divided the lungs into six regions. There were 2 lines dividing the lungs into six regions; the first line was drawn at the level of the inferior wall of the aortic arch and the second line at the level of the right inferior pulmonary vein. Radiologists rate each region from 0 to 3 based on the severity of the lesion. Score 0 for no lung abnormalities, 1 for interstitial infiltrates, 2 for interstitial and alveolar infiltrates (interstitial dominant), and 3 for interstitial and alveolar infiltrates (alveolar

dominant). The score ranges from 0 to 18. Other findings, such as pleural effusion and pulmonary vessel enlargements, were not included in Brixia scoring system.<sup>10</sup>

The RALE scoring system divided the lungs into 2 regions, left and right lung. Each lung is scored from 0 to 4 each; score 0 for no involvement, 1 for less than 25% involvement, 2 for 25%–50% involvement, 3 for 50%–75% involvement, and score 4 for more than 75% involvement. The maximum score for RALE scoring is 8.<sup>14</sup>

The Modified Chest X-ray Scoring System calculated the score or severity from the posteroanterior and anterior projection of CXR by dividing the lungs into 6 regions. Two lines divided the lung horizontally, resulting in each lung into having 3 regions, as shown in (Figure 1). Each region was rated 0 to 2 based on the lesions; score 0 if there is no involvement, 1 if infiltrates or consolidations are less than 50%, and 2 if infiltrates or consolidations are more than 50%. The maximum score for the Modified Chest X-ray scoring system is 12. The final scores were then classified further into mild (score 1–4), moderate (score 5–8) and severe (score 9–12). The example of the application of this scoring system is shown in (Figure 2).

The data were analyzed with IBM SPSS version 25 software. Kolmogorov–Smirnov test was used to assess the normality of the distribution of each scoring system. Spearman correlation test was used to correlate Modified Chest X-Ray scoring system with RALE and Brixia

scoring system. P value of <0.01 was considered statistically significant.

## Results

### Patient Characteristics

The characteristics of patients were summarized in (Table 1). This study included 115 men (51.1%) and 110 women (48.9%), with a mean age of 53 (21–81) years. Most presented with mild pneumonia (29.8%), and no comorbidities (51.1%).

### Chest Radiography Features


Out of 225 patients, 210 patients had abnormal chest radiograph findings as shown in (Table 2). The distribution of lesions was mostly upper, middle and lower zone predominance (103 of 225; 45.6%). A total of 179 out of 225 (79.2%) presented with lesions on bilateral lungs, and 121 out of 225 (53.5%) were peripheral dominant. Other features of CXR included pleural effusion in 28 patients (12.4%) and pulmonary nodules in 33 patients (14.6%).

### Chest Radiography Scoring and Clinical Feature


Based on the RALE scores, most patients of all clinical characteristics scored 5 (17.3%). Asymptomatic patients and those with mild pneumonia mostly scored 2 (11 patients, 4.9%, and 17 patients, 7.6%). Patients with severe pneumonia mostly scored in 5 (9 patients, 4%), while those with ARDS mostly scored 4 and 5 (4 patients, 1.8%). Septic patients mostly scored 7 (7 patients, 3.1%), while patients with septic shock mostly scored 5 (7 patients, 3.1%).

On the other hand, the Brixia scores ranged from 0 to 18. Most patients scored 6 (22 patients, 9.8%). Asymptomatic patients scored 6 (11 patients, 4.9%), while most of the patients with mild pneumonia scored 5 (8 patients, 3.6%); those with severe pneumonia scored 7 (7 patients, 3.1%); those with ARDS patients scored 6; 15, and 18 (2 patients, 0.9%); septic patients scored 6 (5 patients, 2.2%); and septic shock patients scored 14 (6 patients, 2.7%).

The Modified Chest X-ray score ranged from 0 to 12. Most patients scored in 6 (30 patients, 13.3%), while there were no patients who scored 13–17. Asymptomatic patients mostly scored in 6 (11 patients, 4.9%); patients with mild pneumonia mostly scored in 9 (11 patients, 4.9%); patients with severe pneumonia mostly scored in



**Figure 1** Lung field division using Modified Chest X-ray Scoring System on chest posteroanterior (PA) projection. The lung field is divided into six zones lower zone (1 or 2) is under the inferior wall of the lower right pulmonary vein (lung base), middle zones (3 or 4) is below the inferior wall of the aortic arch and above the inferior wall of the lower right pulmonary vein (ie, hilar structures), and upper zone (5 or 6) is above the inferior wall of the aortic arch.



**Figure 2** Two case illustrations of applying Modified Chest X-ray Scoring System on AP projection. (A). The total calculated score of the 6 chest divisions is 4, classified as mild severity score. (B) The total calculated score of the 6 chest divisions is 9, classified as severe severity score.

6 (10 patients, 4.4%). ARDS patients scored in 7 (4 patients, 1.8%); septic patients mostly scored in 5 (6 patients, 2.7%); while patients with septic shock mostly scored in 10 (7 patients, 3.1%).

Based on (Table 3), most patients were classified as severe based on the CXR score classification (92 patients, 40.89%). Most patients with mild CXR score classification also presented with mild clinical presentation (19 patients, 44.19%). Those classified as moderate were mostly asymptomatic and had a clinical feature of mild pneumonia (23 patients, 25.5%), while those classified as severe in

CXR classification mostly had mild pneumonia as a clinical feature (25 patients, 27.17%)

#### Correlation of Chest Radiography Scoring Categorized and Clinical Feature

The correlation coefficient of the CXR was 0.164 ( $p < 0.01$ ).

**Table 1** Sample Characteristic at Presentation

Parameter	No. of Patients (n = 225)
Patient Characteristic	
Male	115 (51.1%)
Female	110 (48.9%)
Age (year)	53 ± 13
Comorbidities	
No comorbid	115 (51.1%)
Hypertension	10 (4.4%)
Obesity	4 (1.8%)
Diabetes	17 (7.6%)
Heart abnormalities	5 (5%)
Other lung abnormalities	6 (2.7%)
Renal abnormalities	4 (1.8%)
Hepatitis	9 (4.0%)
Combine comorbid	40 (6.7%)
Others	15 (6.5%)

**Table 2** Radiographic Findings on Chest Radiographs

Radiographic Characteristic	No. of Findings (n = 225)
Normal chest radiograph	15 (6.6%)
Distribution of lesion	
Upper Zone predominant	1 (0.4%)
Middle Zone predominant	4 (1.8%)
Lower Zone predominant	33 (14.6%)
Upper and Middle zone predominant	3 (1.3%)
Upper and Lower zone predominant	1 (0.4%)
Middle and Lower zone predominant	65 (28.8%)
Upper, Middle, and Lower zone predominant	103 (45.6%)
Right Lung	14 (6.2%)
Left Lung	17 (7.5%)
Bilateral Lung	179 (79.2%)
Peripheral predominant	121 (53.5%)
Perihilar predominant	5 (2.2%)
Peripheral and perihilar predominant	84 (37.2%)
Lung Abnormality Features on chest x-ray	
Reticular-nodular opacities	33 (11.6%)
Patchy opacities	35 (12.4%)
Consolidation	187 (66.1%)
Pleural effusion	28 (9.8%)

**Table 3** Modified Chest X-Ray Scores and Clinical Feature Classification

	Asymptomatic	Mild Pneumonia	Severe Pneumonia	ARDS	Sepsis	Septic Shock	Total
Mild	8	19	5	3	4	4	43
Moderate	23	23	14	7	14	9	90
Severe	11	25	19	5	15	17	92

**Table 4** Analysis Result Spearman Correlation of Modified Chest X-Ray, Brixia and RALE Scores

	Brixia Score	RALE Score
Modified Chest-xray Score	r = 0.865 p < 0.001 n = 225	r = 0.855 p < 0.001 n = 225
RALE Score	r = 0.802 p < 0.001 n = 225	

### Chest Radiography Scoring Correlation with Each Other

The correlation coefficient between the Modified chest X-Ray score and Brixia score was 0.865 ( $p < 0.01$ ), and the correlation coefficient of the Modified chest X-Ray score and RALE score was 0.855 ( $p < 0.01$ ) (Table 4). On the other hand, the correlation coefficient of Brixia and RALE score was slightly lower, which was 0.802 ( $p < 0.01$ ). This indicated that the Modified Chest X-ray Scoring System had a higher correlation coefficient relative to both established Brixia and RALE scoring systems.

## Discussion

In this pandemic, an accurate radiological approach is necessary for a more rapid classification of COVID-19 patients. CXR may not be as sensitive as CT, but it still plays a major role in developing countries that lack more sophisticated modalities. Moreover, CXR can be brought to the patient's bedside, minimizing the risk of cross-infections.<sup>15</sup> Although CXR has a low sensitivity to early-stage disease of COVID-19, it can be used for monitoring the advancement and preceding stages of COVID-19 especially in critical care.<sup>16</sup>

Signorino et al stated that Brixia score system to be a good scoring system that provided detailed presentation and distribution of the lung (6 regions) and a sensibility (4 levels).<sup>17</sup> Borghesi et al also stated that Brixia scoring is a very useful method for ranking the stratification risk of patients with COVID-19 infection based on the severity of cases.<sup>10</sup> However, Brixia scoring requires a trained

radiologist to interpret a CXR, due to its more complex indicators and nature for diagnosing COVID-19 pneumonia. This could be an obstacle for primary healthcare physicians who require an accurate and simple technique for early diagnosis of COVID-19 pneumonia, but lack the knowledge and experience to do so. Meanwhile, RALE scoring can predict supplemental oxygen requirements and the need for ICU admission for mechanical ventilation.<sup>15,18</sup> Compared to Brixia, RALE scoring lacks a detailed and more complex indicator in scoring chest x-rays to diagnose COVID-19 pneumonia. We introduced the use of the Modified Chest X-ray Scoring System at Dr. Soetomo Academic General Hospital and compared it with the established Brixia and RALE scoring systems.

In this study, we found that most of the patients with severe clinical presentation (severe pneumonia, ARDS, sepsis, and septic shock) had 5 or more score with RALE scoring system. Meanwhile, patients with severe clinical presentation had 6 or more score with the Brixia scoring. The Modified Chest X-Ray scoring system showed 5 or more score for patients with severe clinical presentation.

All three scoring systems correlated significantly with one another. Modified Chest X-ray Scoring System of Dr. Soetomo General Hospital correlates more towards Brixia ( $p < 0.01$ , correlation coefficient 0.865) than RALE ( $p < 0.01$ , correlation coefficient 0.855). This result indicates the reliability of Modified Chest X-ray Scoring System in diagnosing COVID-19 pneumonia, and can help in the determination of management of COVID-19 patients early on. However, it should also be noted that COVID-19 patients do not always present with pneumonia.

Modified Chest X-ray Scoring System of Dr. Soetomo General Hospital helps medical professionals in diagnosing COVID-19 pneumonia through a simple and fast method. Further study regarding its efficacy on a larger scale and possibly more heterogeneous cases and should be performed in the hope of its implementation on multiple healthcare center with X-ray devices and without CT scans. Also, study of the correlation of the scoring and the



outcome of care with serial radiographs will add great value to predict patient condition, monitoring progression, later stages of COVID-19, and better management of the disease.

The main limitation of this study is the lack of comparison between the scoring systems and patient's clinical condition because some clinical data were only available in a small percentage of subjects. Another limitation of this study is the lack of comparison between chest x-ray score and patient comorbidities (ie, hypertension, diabetes, cardiovascular disease, and oncologic history) or final outcome.

## Conclusion

Chest radiography can be considered as a tool to diagnose or measure the severity of COVID-19 with certain approach through scoring systems such as Brixia Score, RALE Score, and the Modified Chest X-Ray score of Dr. Soetomo General Hospital, although it may still be less sensitive than CT-Scan. The modified scoring system can help determine COVID-19 patient's severity, especially in areas with shortages of resources and specialists.

## Acknowledgments

A sincere gratitude to all my colleagues, family, and all the patients included in this study.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
- Singhal TA. Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr.* 2020;87(4):281–286. doi:10.1007/s12098-020-03263-6
- Roser M, Ritchie H, Ortiz-Ospina E. Coronavirus @ Ourworldindata. Org [Internet]. 2020. Available from: <https://ourworldindata.org/coronavirus>. Accessed May 13, 2021.
- Volpert V, Banerjee M, D'Onofrio A, Lipniacki T, Petrovskii S, Tran VC. Coronavirus - Scientific insights and societal aspects. *Math Model Nat Phenom.* 2020;15:1–8. doi:10.1051/mmnp/2020010
- Setiati S, Azwar MK. COVID-19 and Indonesia. *Acta medica Indonesiana.* 2020;52(1):84–89.
- Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. *BMJ.* 2020;370.
- Yang R, Li X, Liu H, et al. Chest CT severity score: an imaging tool for assessing severe COVID-19. 2017;282(2):2017.
- Zhang R, Tie X, Qi Z, et al. *Diagnosis of COVID-19 Pneumonia Using Chest Radiography: Value of Artificial Intelligence.* RSNA; 2020.
- Yasin R, Gouda GW. Chest X-ray findings monitoring COVID-19 disease course and severity. *Egypt J Radiol Nucl Med.* 2020;51(1):1. doi:10.1186/s43055-020-00296-x
- Borghesi A, Zigliani A, Masciullo R, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. *Radiol Medica.* 2020;125(5):461–464. doi:10.1007/s11547-020-01202-1
- Wong HYF, Lam HYS, Fong AHT, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. *Radiology.* 2020;296(2):E72–8. doi:10.1148/radiol.2020201160
- Barnard C Age, comorbidities linked to poor COVID-19 outcomes in patients with rheumatic diseases. 2020. Available from: <https://rheumatology.medicinematters.com/covid-19/infection/age-comorbidities-poor-outcomes-patients-rheumatic-diseases/18117812>. Accessed May 13, 2021.
- Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. *Radiol Medica.* 2020;125(5):509–513. doi:10.1007/s11547-020-01200-3.
- Warren MA, Zhao Z, Koyama T, et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. *Thorax.* 2018;73(9):840–846. doi:10.1136/thoraxjnl-2017-211280
- Cozzi D, Albanesi M, Cavigli E, et al. Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome. *Radiol Medica.* 2020;125(8):730–737. doi:10.1007/s11547-020-01232-9
- Wasilewski PG, Mruk B, Mazur S, Póltorak-Szymczak G, Sklinda K, Walecki J. COVID-19 severity scoring systems in radiological imaging – a review. *Polish J Radiol.* 2020;85(1):e361–8. doi:10.5114/pjr.2020.98009
- Signoroni A, Savardi M, Benini S, et al. End-to-end learning for semiquantitative rating of COVID-19 severity on Chest X-rays. 2020; Available from: <http://arxiv.org/abs/2006.04603>. Accessed May 13, 2021.
- Hui TCH, Khoo HW, Young BE, et al. Clinical utility of chest radiography for severe COVID-19. *Quant Imaging Med Surg.* 2020;10(7):1540–1550. doi:10.21037/qims-20-642

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>